Apotex Health Corp. (TSX:APTX) announced that Health Canada has approved SEVMIA™, a generic version of Wegovy® (semaglutide injection) for chronic weight management in adults. According to the company, this marks the first time a generic equivalent of the weight management medication has been authorized in Canada.
SEVMIA™ is supplied as a multi-use pre-filled pen that delivers 1 mg doses. Each pen contains 4 mg of semaglutide at a concentration of 1.34 mg/mL. Apotex developed the product in partnership with Orbicular Pharmaceutical Technologies.
The regulatory approval comes after Health Canada recently approved Apo-Semaglutide Injection™. Apotex said the two approved products broaden its presence across treatments for type 2 diabetes and chronic weight management.
Health Canada’s indication for SEVMIA™ specifies its use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, defined as a body mass index - BMI - of 30 kg/m2 or greater, or in adults who are overweight with a BMI of 27 kg/m2 or greater when at least one weight-related comorbidity is present. The approval also covers use to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease who have a BMI of 27 kg/m2 or greater.
Apotex is headquartered in Toronto and describes itself as a Canadian-based global health company. The organization maintains regional offices in the United States, Mexico, and India, and produces generic, biosimilar, and innovative branded pharmaceuticals in addition to consumer health products.
Summary of the approval
- SEVMIA™ is the first generic equivalent of Wegovy® approved in Canada.
- The product is a multi-use pre-filled pen delivering 1 mg doses, with 4 mg per pen at 1.34 mg/mL concentration.
- The development was carried out in partnership with Orbicular Pharmaceutical Technologies.
Context within Apotex’s portfolio
The SEVMIA™ approval, together with the recent clearance of Apo-Semaglutide Injection™, increases the company’s foothold in treatments that span type 2 diabetes and chronic weight management.
Key points
- Regulatory milestone: SEVMIA™ is the first generic Wegovy® equivalent authorized by Health Canada, extending Apotex’s product lineup in weight-management therapies.
- Product specifics: Offered as a 4 mg per pen, multi-use pre-filled pen delivering 1 mg doses at 1.34 mg/mL concentration.
- Sector impact: The approval touches pharmaceutical manufacturing, branded generics, and consumer health markets through expanded treatment options for obesity and related cardiovascular risk management.
Risks and uncertainties
- Commercial details: The announcement does not provide information on timing, pricing, or distribution plans for SEVMIA™, leaving commercialization dynamics unclear.
- Patient eligibility: The Health Canada indication is limited to specific adult populations defined by BMI thresholds and the presence of weight-related comorbidities, which constrains the indicated patient pool.
- Competitive regulatory activity: The recent approval of another semaglutide product by Health Canada indicates active regulatory movement in this therapeutic area, which could affect market dynamics.
Apotex’s statement highlights its global presence and product scope but does not include further operational or commercial details about roll-out for SEVMIA™. Additional announcements would be required to clarify availability and market strategy.